Sun Pharma slides but global brokerages still expect up to 22% upside, here's why - Moneycontrol

Q1 beat was mainly on lower R&D costs with specialty sales traction continuing in Q1. Improved realisations for Winlevi and Halol plant clearance are the key catalysts, HSBC has said

Sun Pharmaceutical Industries share price was trading almost 3 percent lower at noon on August 1 after the company declared its Q1 earnings. On July 29 Sun Pharma reported a 43 percent growth in con… [+3178 chars]

full article...